Skip to content

Genelux (GNLX) IPO deck

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

This post is for subscribers only

Subscribe

Already have an account? Sign In

Latest